Human tumor antigens recognized by T cells and their implications for cancer immunotherapy

Ryo Ueda, Tomonori Yaguchi, Yutaka Kawakami

Research output: Chapter in Book/Report/Conference proceedingChapter


Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.

Original languageEnglish
Title of host publicationInnate Immune Regulation and Cancer Immunotherapy
PublisherSpringer New York
Number of pages11
ISBN (Print)9781441999146, 9781441999139
Publication statusPublished - 2012 Jan 1

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Human tumor antigens recognized by T cells and their implications for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this